stockrowCytokinetics, Incorporated
CYTK Healthcare Biotechnology
Cytokinetics, Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $88.0 million, up 376.6% from fiscal 2024.
- Revenue
- +2,356.5%
- EPS
- +46.3%
- Free cash flow
- −6.73%
- Total debt
- −83.9%
Quarter to September 2026, against a year earlier
Follow CYTK
Alert me
Cytokinetics, Incorporated (CYTK) Total debt
Cytokinetics, Incorporated's total debt at the end of fiscal 2025 was $1.2B, up 76.1% from $657.1M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $174.4M. Over the past ten years it has ranged from $14.6M (fiscal 2015) to $1.2B (fiscal 2025) — the current reading is the highest in ten years. Cytokinetics, Incorporated ranks 65th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $1.2B | 76.10% |
| FY2024 | $657.1M | 6.42% |
| FY2023 | $617.5M | 1.13% |
| FY2022 | $610.6M | 286.84% |
| FY2021 | $157.8M | 13.79% |
| FY2020 | $138.7M | 3.32% |
| FY2019 | $134.3M | 216.55% |
| FY2018 | $42.4M | 33.47% |
| FY2017 | $31.8M | 6.35% |
| FY2016 | $29.9M | 104.12% |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2026 | $174.4M | (84.80%) |
| Jun 2026 | $1.1B | (1.33%) |
| Mar 2026 | $1.2B | 0.46% |
| Dec 2025 | $1.2B | 6.53% |
| 40 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| ARWR Arrowhead Pharmaceuticals, Inc. compare | $864.1M |
| CAI Caris Life Sciences,�Inc. compare | $393.3M |
| SYRE Spyre Therapeutics, Inc. compare | $387.1M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | $341.3M |
| CYTK Cytokinetics, Incorporated | $174.4M |
| TWST Twist Bioscience Corporation compare | $15.0M |
| KRYS Krystal Biotech, Inc. compare | $8.3M |
| CORT Corcept Therapeutics Incorporated compare | $5.0M |
| PTGX Protagonist Therapeutics, Inc. compare | $1.8M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on CYTK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement